Pfizer sues Amgen in effort to invalidate top cancer drug patent
Pfizer is suing Amgen in Europe over a patent issue, one in which both companies have long gone back and forth.
The brouhaha centers around Amgen’s cancer drug Neulasta, which has faced increasing biosimilar competition over the years. Though the two companies settled a suit in March regarding the drug’s patent, Pfizer submitted a new complaint in a UK court Thursday attempting to throw the patent out altogether.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.